文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

靶区运动缓解促进极低分次前列腺癌放疗的高精度计划与实施:II期研究结果

Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study.
PubMed 文献 · Radiother Oncol · 2020-02-19

该II期研究纳入207例器官局限性前列腺癌患者,给予5次连续9 Gy极低分次放疗,采用直肠内气囊和尿道内Foley导管固定前列腺并监测分次内靶区运动。分次内靶区偏差≤1 mm见于95%的治疗 session,中位随访54个月时低、中、高危组bRFS分别为100%、92.4%和71.4%,晚期2级泌尿和胃肠毒性分别为2.9%和2.4%。

要点

  • 直肠内气囊和尿道导管可实现前列腺每日重复性空间构型固定。
  • 95%治疗 session 分次内靶区偏差≤1 mm,支持高精度剂量雕刻。
  • 5×9 Gy极低分次放疗晚期2级泌尿和胃肠毒性分别为2.9%和2.4%。

核心结论

  • 该前列腺运动缓解协议的空间构型使极高分次5×9 Gy放疗的计划与实施精确,优化了器官局限性前列腺癌的治疗结局。

研究设计与样本

  • II期研究,207例患者接受5次连续9 Gy极低分次放疗。
  • 采用空气膨胀150 cm3直肠内气囊和带3个信标的尿道内Foley导管固定前列腺并监测分次内靶区运动。
  • 采用VMAT-IGRT逆向剂量雕刻给予PTV剂量并满足危及器官剂量体积约束。

主要发现

  • 空气填充气囊诱导直肠/前列腺复合体从静息位置重复迁移至特定耻骨后龛,每日提供相同三维解剖构型。
  • 分次内靶区偏差≤1 mm见于95%的治疗 session,偏差≥2 mm时重新对准可使治疗按计划完成。
  • 中位随访54个月时PSA谷值为0.19 ng/mL,低、中、高危组bRFS分别为100%、92.4%和71.4%。
  • 晚期2级泌尿毒性和胃肠毒性分别为2.9%和2.4%,患者报告的生活质量评分无不良变化。

关键数值与推荐

  • 放疗方案为5次连续9 Gy。
  • 直肠内气囊空气体积为150 cm3。
  • 分次内靶区偏差≤1 mm见于95%的治疗 session。
  • 中位随访54个月时PSA谷值为0.19 ng/mL。
  • 晚期2级泌尿毒性和胃肠毒性分别为2.9%和2.4%。

临床怎么用

  • 对器官局限性前列腺癌行5×9 Gy极低分次放疗时,可采用直肠内气囊联合尿道Foley导管固定前列腺并监测分次内运动。
  • 利用每日重复的三维解剖构型进行逆向剂量雕刻,在满足危及器官剂量体积约束的同时给予PTV剂量。
  • 分次内偏差≥2 mm时进行靶区重新对准以按计划完成治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: While favourable long-term outcomes have been reported in organ-confined prostate cancer treated with 5 × 7-8 Gy extreme hypofractionation, dose escalation to 5 × 9-10 Gy improved local control but was associated with unacceptable rates of late rectal and urinary toxicities. The purpose of this study was to explore the feasibility of intra-fractional prostate immobilization in reducing toxicity, to promote dose escalation with extreme hypofractionated radiotherapy in prostate cancer. MATERIAL AND METHODS: 207 patients received 5 consecutive fractions of 9 Gy. An air-inflated (150 cm3) endorectal balloon and an intraurethral Foley catheter with 3 beacon transponders were used to immobilize the prostate and monitor intra-fractional target motion. VMAT-IGRT with inverse dose-painting was employed in delivering the PTV dose and in sculpting exposure of normal organs at risk to fulfil dose-volume constraints. RESULTS: Introduction of air-filled balloon induced repeatable rectum/prostate complex migration from its resting position to a specific retropubic niche, affording the same 3D anatomical configuration daily. Intra-fractional target deviations ≤1 mm occurred in 95% of sessions, while target realignment in ≥2 mm deviations enabled treatment completion as scheduled. Nadir PSA at median 54 months follow-up was 0.19 ng/mL, and bRFS was 100%, 92.4% and 71.4% in low-, intermediate- and high-risk categories, respectively. Late Grade 2 GU and GI toxicities were 2.9% and 2.4%, respectively. No adverse changes in patient-reported quality of life scores were observed. CONCLUSION: The unique spatial configuration of this prostate motion mitigation protocol enabled precise treatment planning and delivery that optimized outcomes of ultra-high 5 × 9 Gy hypofractionated radiotherapy of organ-confined prostate cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Greco C, Pares O, Pimentel N, et al. Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study. Radiother Oncol. 2020. PMID: 32087469. doi:10.1016/j.radonc.2020.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。